Diovan HCT Paragraph IV Certification Filed
This article was originally published in The Pink Sheet Daily
The first ANDA with a Paragraph IV certification for Novartis' antihypertensive Diovan HCT (valsartan and hydrochlorothiazide) was filed Dec. 2, according to FDA's Feb. 6 updated list of filings
You may also be interested in...
Novartis plans to launch two higher-dose formulations of its hypertensive Diovan HCT (valsartan/hydrochlorothiazide) in early June
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.